Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$4.73 +8.9%	$6.53	$4.22 ▼ $68.70	$8.41M	0.42	226,359 shs	290,839 shs
SNGX Soligenix	$5.29 +90.4%	$1.79	$1.09 ▼ $6.23	$17.33M	1.95	4.33 million shs	163.94 million shs
TSBX Turnstone Biologics	$0.36	$0.36	$0.29 ▼ $2.42	$8.22M	1.36	142,319 shs	N/A
VGLS VG Life Sciences	$0.00	$0.00	$0.00 ▼ $0.00	$2.11M	1.67	7.28 million shs	54,000 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	-8.25%	-13.03%	-43.38%	-92.87%
SNGX Soligenix	0.00%	-4.14%	+104.41%	+47.87%	-26.84%
TSBX Turnstone Biologics	0.00%	0.00%	-1.63%	+3.59%	-53.39%
VGLS VG Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLRB Cellectar Biosciences	2.7589 of 5 stars	3.3	2.0	0.0	0.0	3.0	1.7	1.3
SNGX Soligenix	1.8956 of 5 stars	3.5	2.0	0.0	0.0	2.1	0.0	0.6
TSBX Turnstone Biologics	3.3043 of 5 stars	2.8	5.0	0.0	0.0	2.7	2.5	1.3
VGLS VG Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.50	Moderate Buy	$375.00	8,289.26% Upside
SNGX Soligenix	3.00	Buy	$6.00	5.41% Upside
TSBX Turnstone Biologics	1.50	Reduce	$0.45	26.76% Upside
VGLS VG Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VGLS, SNGX, CLRB, and TSBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	CLRB Cellectar Biosciences	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/16/2025	SNGX Soligenix	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $6.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$8.98 per share	N/A
SNGX Soligenix	$120K	154.63	N/A	N/A	$1.64 per share	3.47
TSBX Turnstone Biologics	$19.31M	0.43	N/A	N/A	$0.64 per share	0.55
VGLS VG Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$44.58M	-$19.91	N/A	N/A	N/A	N/A	-453.09%	-132.55%	N/A
SNGX Soligenix	-$8.27M	-$3.80	N/A	N/A	N/A	N/A	-233.65%	-117.43%	N/A
TSBX Turnstone Biologics	-$70.84M	-$2.05	N/A	N/A	N/A	N/A	-171.86%	-128.13%	N/A
VGLS VG Life Sciences	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VGLS, SNGX, CLRB, and TSBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLRB Cellectar Biosciences	-$3.60	-$3.39	+$0.21	-$3.39	N/A	N/A
8/14/2025	Q2 2025	SNGX Soligenix	-$0.79	-$0.82	-$0.03	-$0.82	N/A	N/A
8/8/2025	Q2 2025	TSBX Turnstone Biologics	-$0.16	-$0.24	-$0.08	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A
TSBX Turnstone Biologics	N/A	N/A	N/A	N/A	N/A
VGLS VG Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	2.47	2.47
SNGX Soligenix	N/A	1.85	1.85
TSBX Turnstone Biologics	N/A	3.33	3.70
VGLS VG Life Sciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
SNGX Soligenix	3.60%
TSBX Turnstone Biologics	52.51%
VGLS VG Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	5.04%
SNGX Soligenix	3.05%
TSBX Turnstone Biologics	32.10%
VGLS VG Life Sciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
SNGX Soligenix	20	3.26 million	3.16 million	Not Optionable
TSBX Turnstone Biologics	82	23.14 million	15.71 million	Not Optionable
VGLS VG Life Sciences	1	21.10 billion	N/A	Not Optionable

VGLS, SNGX, CLRB, and TSBX Headlines

Recent News About These Companies

VGLS VG Life Sciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Camfil USA Unveils Absolute® VG: Advanced V-Bank HEPA Filters with Gasket and Gel Seals

October 31, 2024 | markets.businessinsider.com

VG Life Sciences Inc.

September 14, 2024 | barrons.com

VG Life Sciences, Inc. Increases Authorized Shares

August 16, 2024 | br.advfn.com

VG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10

August 16, 2024 | br.advfn.com

VG Life Sciences Inc. (VGLS)

March 1, 2024 | finance.yahoo.com

VG Life Sciences Stock (OTC:VGLS), Insider Trading Activity

February 27, 2024 | benzinga.com

Emerging from a Recent Pullback, Life Sciences Has a Pulse

January 18, 2024 | globest.comG

VG Life Sciences Inc VGLS

November 16, 2023 | morningstar.comM

Report warns of 'oversupply' of life sciences real estate

September 17, 2023 | bizjournals.com

VGLS VG Life Sciences Inc.

February 16, 2023 | seekingalpha.com

The best Life is Strange game is on PlayStation Plus right now – and it’s not what you think

January 26, 2023 | vg247.comV

New MarketBeat Followers Over Time

Media Sentiment Over Time

VGLS, SNGX, CLRB, and TSBX Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$4.72 +0.39 (+8.87%)

As of 02:44 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Soligenix NASDAQ:SNGX

$5.29 +2.51 (+90.40%)

As of 02:44 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Turnstone Biologics NASDAQ:TSBX

$0.36 0.00 (0.00%)

As of 08/11/2025

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

VG Life Sciences OTCMKTS:VGLS

$0.0001 0.00 (0.00%)

As of 09:30 AM Eastern

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time